Research profile
BPC-157
BPC-157 has been studied in animal models of tissue injury and inflammation. Ulcerative colitis was among the proposed uses reviewed by FDA staff.
- Predominantly preclinical evidence
- Evaluation only
Amnavero
BPC-157
What the research found
FDA’s review did not identify studies in people with ulcerative colitis using the proposed oral, subcutaneous, nasal, or transdermal routes.
What remains uncertain
Animal findings leave open whether BPC-157 helps people heal, and the limited human evidence leaves important safety questions.